Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity

Xu Han, Zhifeng Jing, Wei Wu, Bing Zou, Zhili Peng, Pengyu Ren, Athula Wikramanayake, Zhongmin Lu, Roger Leblanc

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Amyloid-β peptide (Aβ) fibrillation is pathologically associated with Alzheimer's disease (AD), and this has resulted in the development of an Aβ inhibitor which is essential for the treatment of AD. However, the design of potent agents which can target upstream secretases, inhibit Aβ toxicity and aggregation, as well as cross the blood-brain barrier remains challenging. In, this research carbon dots for AD treatment were investigated in vitro using experimental and computational methods for the first time. The results presented here demonstrate a novel strategy for the discovery of novel antiamyloidogenic agents for AD treatments.

Original languageEnglish (US)
Pages (from-to)12862-12866
Number of pages5
JournalNanoscale
Volume9
Issue number35
DOIs
StatePublished - Sep 21 2017

ASJC Scopus subject areas

  • Materials Science(all)

Fingerprint Dive into the research topics of 'Biocompatible and blood-brain barrier permeable carbon dots for inhibition of Aβ fibrillation and toxicity, and BACE1 activity'. Together they form a unique fingerprint.

  • Cite this